Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasm, Residual × Immunotherapy, Adoptive × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Lymphoma, Non-Hodgkin 6 Lymphoma, B-Cell 6 Recurrence 4 Multiple Myeloma 4 Lymphoma 3 Leukemia, Myeloid, Acute 3 Lymphoma, Follicular 2 Leukemia 2 Burkitt Lymphoma 2 Solid Tumors 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Pyloric Stenosis, Hypertrophic 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Pleural Effusion, Malignant 1 Platinum-Resistant Ovarian Carcinoma 1 Plasmacytoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Neoplasm, Residual 1 Nasopharyngeal Carcinoma 1 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cyclophosphamide 7 venetoclax 6 Azacitidine 6 fludarabine 5 Cytarabine 4 Blood Specimen Collection 4 daratumumab 3 blinatumomab 3 Daunorubicin 3 tislelizumab 2 fludarabine phosphate 2 Liquid Biopsy 2 Lenalidomide 2 Idarubicin 2 Gemtuzumab 2 Capecitabine 2 Busulfan 2 trastuzumab deruxtecan 1 thymoglobulin 1 tetrathiomolybdate 1 talquetamab 1 tagraxofusp 1 sugemalimab 1 sacituzumab govitecan 1 relugolix 1 pembrolizumab 1 pegaspargase 1 palbociclib 1 obinutuzumab 1 ivosidenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280494 2025-12-12

S101MRD

Peking University People's Hospital

Phase 1 Recruiting

Lymphoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡